Literature DB >> 31188013

Loss of cells expressing fibroblast activation protein has variable effects in models of TGF-β and chronic bleomycin-induced fibrosis.

Toru Kimura1, James Monslow2, Astero Klampatsa1, Michael Leibowitz1, Jing Sun1, Maria Liousia1, Patrick Woodruff1, Edmund Moon1, Leslie Todd2, Ellen Puré2, Steven M Albelda1.   

Abstract

Fibroblast activation protein (FAP), a cell surface serine protease, is upregulated on a subset of activated fibroblasts (often distinct from α-smooth muscle actin-expressing myofibroblasts) associated with matrix remodeling, including fibroblasts in idiopathic pulmonary fibrosis (Acharya PS, Zukas A, Chandan V, Katzenstein AL, Puré E. Hum Pathol 37: 352-360, 2006.). As FAP+ fibroblasts could be pivotal in either breakdown and/or production of collagen and other matrix components, the goal of this study was to define the role of FAP+ cells in pulmonary fibrosis in two established, but different, mouse models of chronic lung fibrosis: repetitive doses of intratracheal bleomycin and a single dose of an adenoviral vector encoding constitutively active TGF-β1 (Ad-TGFβ). To determine their role in fibrotic remodeling, FAP-expressing cells were depleted by injection of T cells expressing a chimeric antigen receptor specific for murine FAP in mice with established fibrosis. The contribution of FAP to the function of FAP-expressing cells was assessed in FAP knockout mice. Using histological analyses, quantification of soluble collagen content, and flow cytometry, we found that loss of FAP+ cells exacerbated fibrosis in the bleomycin model, a phenotype largely recapitulated by the genetic deletion of FAP, indicating that FAP plays a role in this model. In contrast, depletion of FAP+ cells or genetic deletion of FAP had little effect in the Ad-TGFβ model highlighting the potential for distinct mechanisms driving fibrosis depending on the initiating insult. The role of FAP in human lung fibrosis will need to be well understood to guide the use of FAP-targeted therapeutics that are being developed.

Entities:  

Keywords:  adoptive T-cell transfer; animal models; chimeric antigen receptors; chronic pulmonary fibrosis; fibroblast activation protein; matrix remodeling

Mesh:

Substances:

Year:  2019        PMID: 31188013     DOI: 10.1152/ajplung.00071.2019

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  8 in total

Review 1.  CAR-based therapies: opportunities for immuno-medicine beyond cancer.

Authors:  Haig Aghajanian; Joel G Rurik; Jonathan A Epstein
Journal:  Nat Metab       Date:  2022-02-28

2.  The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG.

Authors:  Lianjun Lan; Hanxiang Liu; Yingwei Wang; Jia Deng; Dengsai Peng; Yue Feng; Li Wang; Yue Chen; Lin Qiu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-19       Impact factor: 9.236

3.  microRNA-30a attenuates TGF-β1-induced activation of pulmonary fibroblast cell by targeting FAP-α.

Authors:  Geting Wu; Bin Xie; Can Lu; Chen Chen; Jianhua Zhou; Zhenghao Deng
Journal:  J Cell Mol Med       Date:  2020-01-28       Impact factor: 5.310

4.  Effects of bone morphogenetic protein 4 on TGF-β1-induced cell proliferation, apoptosis, activation and differentiation in mouse lung fibroblasts via ERK/p38 MAPK signaling pathway.

Authors:  Zhou Cai; Hua Guo; Jing Qian; Wei Liu; Yuanyuan Li; Liang Yuan; You Zhou; Ran Lin; Xiaohui Xie; Qiong Yang; Guoying Wu; Qiongqiong Li; Li Zhao; Fei Liu; Jian Wang; Wenju Lu
Journal:  PeerJ       Date:  2022-07-27       Impact factor: 3.061

Review 5.  Macrophage-stroma interactions in fibrosis: biochemical, biophysical, and cellular perspectives.

Authors:  Gwenda F Vasse; Mehmet Nizamoglu; Irene H Heijink; Marco Schlepütz; Patrick van Rijn; Matthew J Thomas; Janette K Burgess; Barbro N Melgert
Journal:  J Pathol       Date:  2021-03-03       Impact factor: 7.996

Review 6.  The Blood Circulating Rare Cell Population. What is it and What is it Good For?

Authors:  Stefan Schreier; Wannapong Triampo
Journal:  Cells       Date:  2020-03-25       Impact factor: 6.600

7.  YAP is essential for TGF-β-induced retinal fibrosis in diabetic rats via promoting the fibrogenic activity of Müller cells.

Authors:  Wei Zhang; Yichun Kong
Journal:  J Cell Mol Med       Date:  2020-09-20       Impact factor: 5.310

Review 8.  Targeting Dermal Fibroblast Subtypes in Antifibrotic Therapy: Surface Marker as a Cellular Identity or a Functional Entity?

Authors:  Xin Huang; Yimin Khoong; Chengyao Han; Dai Su; Hao Ma; Shuchen Gu; Qingfeng Li; Tao Zan
Journal:  Front Physiol       Date:  2021-07-15       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.